BCYC vs DNA

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a remarkable 338.5% year-over-year revenue growth and strong analyst target price of $21.50 implying 210% upside, the company continues to report deep operating losses (-558.64% operating margin), deteriorating earnings (YoY EPS growth of -18.1%), and inconsistent earnings surprises, with only 1 out of the last 4 quarters beating estimates. High valuation multiples (Price/Sales of 17.01) contrast with negative profitability and weak insider sentiment, while recent insider selling adds downward pressure. Although the balance sheet appears strong with a current ratio of 10.66 and minimal debt, the lack of profitability and cash flow transparency limits confidence in sustainable recovery.

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and operational deterioration. Despite a strong current ratio of 4.92 providing a short-term liquidity buffer, the company is facing a systemic collapse in growth with YoY revenue declining by 23.80%. Massive negative operating margins (-209.74%) and a catastrophic 5-year price decline of 98.1% suggest a failing business model. The combination of shrinking top-line revenue and bearish insider selling confirms a high-risk profile.